| Literature DB >> 32678224 |
Hongqin Xu1, Junqi Niu2,3, Yanhang Gao4, Yanqing Li4, Xiaowen Liu4, Tong Zhang4, Ge Yu4, Yang Wang4, Ying Shi4, Xiumei Chi4,5, Xiaomei Wang4, Xiuzhu Gao4,5, Ruihong Wu4,5, Yingyu Zhang4, Lei Hang4, Shijuan Sun4, Yazhe Guan4, Ying Xu4, Jing Meng4, Xu Liu4, Chang Jiang4, Heming Ma4, Liting Luo4, Qi Yan4, Xin Yin4, Fei Peng4, Yixiao Zhi4, Weige Qu4, Xia Zhang4, Tianqi Ren4, Lili Liu4, Jinming Zhao4, Feiyu Zhang4, Adila Yakepu4, Yu Pan4.
Abstract
In China, the prevalence of Clonorchis sinensis (C. sinensis) infections is only evaluated at the provincial level by national sampling surveys, and data from villages and counties are still lacking. In this study, we conducted a cross-sectional survey in 10 villages located along the Lalin River in northeast China. Clonorchiasis was diagnosed using a modified Kato-Katz method that detects the C. sinensis egg in stools. A total of 3,068 persons were screened and 2,911 were recruited for the study. Overall, the prevalence of C. sinensis infection was 29.3%. Among 175 participants who were cured after antiparasitic treatment, 54 (30.86%) were re-infected in this survey. After calibration of potential confounders, male gender, occupation as a farmer, smoking, and occasionally or frequently eating raw fish were independent risk factors for C. sinensis infection. The results of laboratory examinations in the C. sinensis/hepatitis B or C virus co-infection group were similar to those in the hepatitis B or C virus mono-infection groups. In conclusion, C. sinensis is highly endemic in villages along the Lalin River, and the primary route of infection is the consumption of raw freshwater fish. Co-infection with C. sinensis did't aggravate the clinical manifestations of viral hepatitis in this cross-sectional study.Entities:
Mesh:
Year: 2020 PMID: 32678224 PMCID: PMC7366707 DOI: 10.1038/s41598-020-68684-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Univariate and multivariate analysis of socio-demographic characteristics by Clonorchis sinensis infection among residents in riverside villages.
| Variable | Total N | Clonorchiasis + N (%) | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|---|
| Odds ratio (95% CI) | OR | 95% CI for OR | |||||
| Total | 2,911 | 854 (29.3) | – | – | – | – | – |
| Female | 1,415 | 265 (18.7) | – | – | Reference | Reference | Reference |
| Male | 1,496 | 589 (39.4) | 2.818 (2.380–3.337) | < 0.001 | 1.95 | 1.58–2.40 | < 0.001 |
| ≤ 30 years old | 95 | 16 (16.8) | – | 0.005 | – | – | – |
| 31–60 | 2056 | 631 (30.7) | 2.186 (1.267–3.772) | 0.004 | – | – | – |
| ˃ 60 years old | 760 | 207 (27.2) | 1.848 (1.055–3.237) | 0.03 | – | – | – |
| College | 167 | 29 (17.4) | – | < 0.001 | – | – | – |
| Middle school | 1,015 | 339 (33.4) | 2.386 (1.566–3.636) | < 0.001 | – | – | – |
| Primary school | 1729 | 486 (28.1) | 1.861 (1.230–2.814) | 0.003 | – | – | – |
| Non-farmer | 278 | 49 (17.6) | – | – | Reference | Reference | Reference |
| Farmer | 2,633 | 805 (30.6) | 2.058 (1.495–2.833) | 0.000 | 2.31 | 1.66–3.22 | < 0.001 |
| No | 1675 | 432 (25.8) | – | 0.000 | Reference | Reference | Reference |
| Yes | 1,092 | 384 (35.2) | 1.561 (1.322–1.842) | < 0.001 | 1.1 | 0.92–1.32 | 0.302 |
| Quit smoking | 144 | 38 (26.4) | 1.031 (0.701–1.518) | 0.875 | 0.68 | 0.45–1.03 | 0.069 |
| No | 1985 | 463 (23.3) | – | 0.000 | Reference | Reference | Reference |
| Yes | 816 | 352 (43.1) | 2.494 (2.097–2.965) | 0.000 | 1.31 | 1.06–1.63 | 0.013 |
| quit drinking | 110 | 39 (35.5) | 1.806 (1.205–2.705) | 0.004 | 1.11 | 0.71–1.73 | 0.649 |
| Never | 1,049 | 154 (14.7) | – | 0.000 | Reference | Reference | Reference |
| Occasionally | 1787 | 660 (36.9) | 3.403 (2.797–4.141) | 0.000 | 2.58 | 2.10–3.18 | < 0.001 |
| Frequently | 75 | 40 (53.3) | 6.642 (4.090–10.785) | 0.000 | 3.93 | 2.38–6.51 | < 0.001 |
| No | 1928 | 544 (28.2) | – | – | – | – | – |
| Yes | 983 | 310 (31.5) | 1.172 (0.992–1.385) | 0.063 | – | – | – |
| No | 2,594 | 753 (29.0) | – | 0.039 | – | – | – |
| Yes | 165 | 62 (37.6) | 1.471 (1.062–2.039) | 0.02 | – | – | – |
| Unclear | 152 | 39 (25.7) | 0.844 (0.581–1.226) | 0.373 | – | – | – |
| No | 1909 | 578 (30.3) | – | 0.263 | |||
| Yes | 850 | 237 (27.9) | 0.890 (0.745,1.06) | 0.203 | |||
| Unclear | 152 | 39 (25.7) | 0.795 (0.545,1.159) | 0.231 | |||
Baseline characteristics of HCV/C. sinensis co-infection group and HCV or C. sinensis mono-infection groups.
| Hepatitis B (n = 46) | HBV/ | ||||
|---|---|---|---|---|---|
| Age (years, mean ± SD) | 50.59 ± 10.01 | 50.65 ± 9.81 | 50.63 ± 9.76 | 0.999 | 0.999 |
| Sex (Male, %) | 31 (67.4) | 31 (67.4) | 31 (67.4) | 1.000 | 1.000 |
| ALT (IU/mL) | 41.0 (34.3, 49.5) | 38.5 (32.8, 51.0) | 39.5 (30.5, 49.3) | 0.56 | 0.912 |
| AST (IU/mL) | 33.0 (26.0, 42.5) | 32.5 (27.8, 39.0) | 29.5 (25.0, 40.3) | 0.922 | 0.137 |
| Total protein (g/L) | 78.0 (72.8, 84.3) | 77.0 (72.0, 83.3) | 78.5 (72.0, 81.3) | 0.46 | 0.587 |
| ALB (g/L) | 44.5 (41.0, 48.3) | 44.0 (41.0, 47.0) | 44.5 (42.0, 46.0) | 0.45 | 0.543 |
| ALB/GLB | 1.40 (1.08, 1.52) | 1.36 (1.19, 1.54) | 1.34 (1.17, 1.59) | 0.934 | 0.936 |
| TBIL (µmol/L) | 18.0 (13.0, 23.0) | 18.0 (14.0, 22.0) | 17.0 (13.8, 21.0) | 0.745 | 0.766 |
| IBIL (µmol/L) | 11.0 (6.75, 16.0) | 9.0 (7.0, 14.0) | 10.0 (6.0, 13.0) | 0.484 | 0.829 |
| GGT (U/L) | 28.5 (18.8, 59.5) | 31.5 (21.8, 74.3) | 33.5 (24.8, 65.8) | 0.292 | 0.614 |
| ALP (U/L) | 69.0 (50.0, 83.0) | 61.5 (45.5, 72.3) | 67.0 (53.8, 79.5) | 0.184 | 0.183 |
| Creatinine (μmol/L) | 62.0 (54.5, 73.0) | 64.5 (58.0, 70.5) | 63.5 (55.5, 75.3) | 0.763 | 0.699 |
| BUN (mmol/L) | 5.1 (4.4, 5.9) | 5.25 (4.50, 6.03) | 5.5 (4.6, 6.2) | 0.716 | 0.39 |
| Uric acid (µmol/L) | 354 (304, 435) | 362.0 (308.3, 422.8) | 360.0 (311.5, 435.3) | 0.679 | 0.885 |
| TG (mmol/L) | 1.34 (0.95, 1.83) | 1.52 (1.11, 2.20) | 1.79 (1.19, 2.91) | 0.226 | 0.328 |
| Cholesterol (mmol/L) | 3.45 (2.80, 3.88) | 3.60 (3.10, 4.30) | 3.90 (3.30, 4.50) | 0.088 | 0.148 |
| LDL (mmol/L) | 1.23 (0.91, 1.56) | 1.40 (0.88, 2.02) | 1.45 (1.12, 2.08) | 0.517 | 0.293 |
| GLU (mmol/L) | 3.40 (3.10, 3.55) | 3.80 (3.30, 4.90) | 3.50 (3.25, 4.15) | 0.388 | 0.873 |
| WBC (*109/L) | 6.96 (6.22, 8.27) | 6.78 (5.75, 7.90) | 6.73 (5.81, 7.63) | 0.571 | 0.932 |
| RBC (*1,012/L) | 4.64 (4.23, 5.15) | 4.64 (4.16, 5.00) | 4.67 (4.40, 4.97) | 0.363 | 0.679 |
| PLT (*109/L) | 159.5 (133.8, 190.0) | 161.0 (129.8, 198.0) | 178.5 (145.8, 216.5) | 0.767 | 0.135 |
| Lymphocyte (*109/L) | 2.27 (1.89, 3.04) | 2.41 (1.95, 3.04) | 2.38 (1.96, 2.71) | 0.87 | 0.582 |
| Neutrophil (*109/L) | 3.75 (3.27, 4.22) | 3.51 (2.80, 4.30) | 3.29 (2.90, 4.26) | 0.461 | 0.746 |
| Eosinophil count (*109/L) | 0.15 (0.11, 0.21) | 0.18 (0.12, 0.34) | 0.19 (0.12, 0.42) | 0.509 | 0.673 |
| Haemoglobin (g/L) | 153.5 (139.0, 169.3) | 155.5 (134.5, 167.0) | 152.5 (144, 160) | 0.54 | 0.749 |
| lg10 (HBV-DNA) | 3.39 (2.30, 4.63) | 2.91 (2.36, 5.60) | – | 1 | – |
| APRI | 0.45 (0.31, 0.62) | 0.47 (0.33, 0.65) | 0.38 (0.28, 0.47) | 0.904 | 0.049 |
| FIB-4 | 1.70 (1.12, 2.44) | 1.65 (1.08, 2.69) | 1.28 (1.02, 1.80) | 0.907 | 0.082 |
ALT alanine aminotransferase, AST aspartate aminotransferase, ALB albumin, GLB globulin, ALB/GLB albumin to globulin, TBIL total bilirubin, IBIL indirect bilirubin, GGT gamma-glutamyl transpeptidase, ALP alkaline phosphatase, BUN blood urea nitrogen, TG triglyceride, LDL low-density lipoprotein, GLU glucose, WBC white blood cell, RBC red blood cell, PLT platelet, APRI, levels and AST to PLT ratio index, FIB-4 fibrosis-4 scores.
Baseline characteristics of HBV/C. sinensis co-infection group and HBV or C. sinensis mono-infection groups.
| Hepatitis C (n = 59) | HCV/ | ||||
|---|---|---|---|---|---|
| Age (years, mean ± SD) | 57.78 ± 7.91 | 57.54 ± 8.47 | 57.46 ± 8.33 | 0.876 | 0.956 |
| Sex (Male, %) | 46 (78.0) | 46 (78.0) | 46 (78.0) | 1.000 | 1.000 |
| ALT (IU/mL) | 54.0 (41.0, 81.0) | 62.0 (42.0, 103.0) | 38.0 (31.0, 48.0) | 0.236 | < 0.001 |
| AST (IU/mL) | 45.0 (32.0, 67.0) | 54.0 (38.0, 87.0) | 28.0 (24.0, 35.0) | 0.052 | < 0.001 |
| Total protein (g/L) | 78.0 (72.0, 85.0) | 79.0 (75.0, 85.0) | 77.0 (72.0, 82.0) | 0.292 | 0.031 |
| ALB (g/L) | 43.0 (41.0, 45.0) | 43.0 (42.0, 45.0) | 44.0 (42.0, 46.0) | 0.184 | 0.539 |
| ALB/GLB | 1.22 (1.07, 1.43) | 1.18 (1.09, 1.35) | 1.36 (1.23, 1.53) | 0.51 | 0.001 |
| TBIL (µmol/L) | 17.0 (12.0, 22.0) | 19.0 (14.0, 24.0) | 16.0 (13.0, 20.0) | 0.164 | 0.036 |
| IBIL (µmol/L) | 10.0 (6.0, 13.0) | 11.0 (7.0, 15.0) | 9.0 (6.0, 12.0) | 0.111 | 0.025 |
| GGT (U/L) | 53.0 (29.0, 104.0) | 69.0 (37.0, 143.0) | 36.0 (25.0, 69.0) | 0.114 | 0.001 |
| ALP (U/L) | 73.0 (61.0, 93.0) | 78.0 (61.0, 93.0) | 70.0 (56.0, 81.0) | 0.577 | 0.035 |
| Creatinine (μmol/L) | 65.0 (58.0, 73.0) | 65.0 (56.0, 75.0) | 66.0 (58.0, 74.0) | 0.732 | 0.724 |
| BUN (mmol/L) | 5.5 (4.5, 6.6) | 5.80 (4.60, 6.60) | 5.5 (4.8, 6.2) | 0.628 | 0.554 |
| Uric acid (µmol/L) | 363.0 (330.0, 404.0) | 377.0 (315.0, 424.0) | 365.0 (305.0, 438.0) | 0.317 | 0.844 |
| TG (mmol/L) | 1.38 (0.85, 1.73) | 1.28 (0.89, 2.04) | 1.54 (1.19, 2.54) | 0.861 | 0.020 |
| Cholesterol (mmol/L) | 3.30 (2.80, 3.70) | 3.30 (2.90, 4.00) | 3.80 (3.20, 4.40) | 0.425 | 0.003 |
| LDL (mmol/L) | 1.22 (0.91, 1.68) | 1.27 (0.87, 1.77) | 1.66 (1.16, 2.23) | 0.998 | 0.011 |
| GLU (mmol/L) | 3.85 (3.53, 4.05) | 4.10 (3.60, 4.40) | 3.70 (3.35, 6.48) | 0.377 | 0.535 |
| WBC (*109/L) | 6.28 (4.82, 7.73) | 6.02 (5.12, 7.30) | 6.81 (5.83, 8.09) | 0.72 | 0.012 |
| RBC (*1,012/L) | 4.49 (4.28, 4.97) | 4.57 (4.18, 4.93) | 4.64 (4.34, 4.85) | 0.901 | 0.825 |
| PLT (*109/L) | 144.0 (102.0, 179.0) | 136.0 (106.0, 176.0) | 180.0 (147.0, 215.0) | 0.677 | < 0.001 |
| Lymphocyte (*109/L) | 2.12 (1.73, 2.68) | 2.00 (1.73, 2.49) | 2.30 (1.97, 2.53) | 0.62 | 0.029 |
| Neutrophil (*109/L) | 3.28 (2.29, 4.66) | 3.30 (2.63, 4.03) | 3.62 (2.88, 4.40) | 0.733 | 0.039 |
| Eosinophil count (*109/L) | 0.15 (0.09, 0.20) | 0.17 (0.11, 0.28) | 0.25 (0.16, 0.47) | 0.177 | 0.004 |
| Haemoglobin (g/L) | 152.0 (144.0, 161.0) | 153.0 (142.0, 164.0) | 153.0 (145.0, 161.0) | 0.784 | 0.981 |
| lg (HCV-RNA) | 6.43 (5.71, 6.92) | 6.27 (5.49, 6.82) | – | 0.587 | – |
| HCV-Genotype (1b, %) | 32 (54.2) | 27 (45.8) | – | 0.361 | – |
| APRI | 0.74 (0.49, 1.47) | 0.88 (0.55, 1.88) | 0.35 (0.28, 0.52) | 0.156 | < 0.001 |
| FIB-4 | 2.54 (1.65, 4.22) | 3.01 (1.93, 5.39) | 1.52 (1.18, 2.08) | 0.188 | < 0.001 |
ALT alanine aminotransferase, AST aspartate aminotransferase, ALB albumin, GLB globulin, ALB/GLB albumin to globulin, TBIL total bilirubin, IBIL indirect bilirubin, GGT gamma-glutamyl transpeptidase, ALP alkaline phosphatase, BUN blood urea nitrogen, TG triglyceride, LDL low-density lipoprotein, GLU glucose, WBC white blood cell, RBC red blood cell, PLT platelet, APRI, levels and AST to PLT ratio index, FIB-4 fibrosis-4 scores.
Figure 1Clonorchis sinensis re-infection rate in this survey. Among 766 people who received quinolone treatment, 175 were cured after treatment, 561 were not reviewed, and 30 were not cured at one-month follow-up. Among the 175 people who were cured after the first treatment, 54 people were re-infected, accounting for 30.86%.